A Phase 4 interventional study of Romosozumab and Teriparatide in Osteoporosis, Postmenopausal and Osteoporosis, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing teriparatide in Osteoporosis, Postmenopausal — 1 open to participants now, 1 under way, none of them phase 3. Teriparatide · Osteoporosis, Postmenopausal.
Among the 23 studies testing teriparatide in Osteoporosis, Postmenopausal, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 in phase 4, and was the 22nd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 23 studies testing teriparatide in Osteoporosis, Postmenopausal is open now, in 1 country.
By country, each count listing its studies:
Teriparatide: first FDA approval 2002 (FORTEO), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 45 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 75 across the 22 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 23 have an industry lead sponsor. The 5 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
11 studies in Osteoporosis, Postmenopausal by Massachusetts General Hospital: 3 open now, 5 under way, none of them phase 3. Of 5 finished, 4 (80%) have results posted.
Among the 11 studies in Osteoporosis, Postmenopausal by Massachusetts General Hospital, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 4, and was the 10th registered.
Massachusetts General Hospital’s Osteoporosis, Postmenopausal studies by the year they started, since 1999.
1 of the studies testing teriparatide in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06558188Massachusetts General HospitalCombined Anabolic Therapy | 2027-11-02 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing teriparatide in Osteoporosis, Postmenopausal, from their registry updates:
Among Massachusetts General Hospital’s 11 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
romosozumab
Drug: Romosozumab
romosozumab and teriparatide
Drug: Romosozumab · Drug: Teriparatide
romosozumab 210 milligrams monthly
Also known as: Evenity
teriparatide 20 micrograms daily
Also known as: Forteo
Lumbar spine areal bone mineral density
Change in lumbar spine bone density between month 0 and month 12
Time frame: Month 0 to 12
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Nov 2027, 32 months after the start.
Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 32 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2027 → Nov 2027 and completion Apr 2028 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teriparatide
Osteoporosis, Postmenopausal →
Massachusetts General Hospital →